The FDA Puts Meat and Drug Industry Interests Ahead of Public Health - Again
The U.S. Food and Drug Administration (FDA) has finalized Guidance for Industry #273 (GFI #273), a policy that was supposed to help address one of the greatest public health threats of our time: antibiotic resistance.
Instead, the agency has handed decision-making power to the meat industry. The industry that is primarily creating the problem of antibiotic overuse and driving antibiotic resistance.
What GFI #273 Does and Why It Matters
GFI #273 directs drug companies to establish limits on how long medically important antibiotics (drugs shared between people and animals) can be fed to food animals. Some of these antibiotics, which were approved for use a long time ago, can currently be given to animals continuously, for the entire life of the animal. This is a major contributor to antibiotic resistance. More exposure over time to an antibiotic means a higher risk of antibiotic resistance developing. The FDA has long recognized this as a problem and, for over ten years, has been working to create a process to add limits on how long these antibiotic drugs can be used. This should be a very positive step for antibiotic stewardship.
But here’s the problem: in its final rule, the FDA is allowing drug manufacturers to set those duration limits based primarily on what works for animal production, not what protects public health. Companies are not required to factor antibiotic resistance risk into their proposed duration limits, leaving the door wide open for routine continuous feeding of antibiotics to animals on factory farms.
This turns the FDA’s responsibility upside down.
Antibiotic resistance develops when bacteria are repeatedly exposed to antibiotics over time. Feeding antibiotics to animals for weeks or even months creates ideal conditions for resistant “superbugs” to emerge. These resistant bacteria can spread:
Between animals
From animals to farm workers
Through meat products
Into surrounding communities and the environment
The result? Hard-to-treat infections in both people and animals.
FDA Has Done Better Before
This isn’t the first time the agency has addressed antibiotic resistance risk. Back in 2003, under Guidance for Industry #152 (GFI #152), the FDA established a public-health framework that generally capped antibiotic use at 21 days when a new use posed a resistance risk.
That was a science-based safeguard.
Yet under GFI #273, those clear public-health guardrails are missing. Instead of applying a consistent resistance-risk standard, the agency now allows duration decisions to be driven primarily by animal production considerations.
Antibiotic policy should be grounded in public health - not production efficiency.
Preventive Use Still Allowed
Even more troubling, the final guidance still does not prohibit the preventive use of antibiotics in animals that are not sick.
Preventive use is a major driver of antibiotic overuse in industrial animal agriculture. Crowded, stressful, and unsanitary conditions make disease more likely, and antibiotics are often used to compensate for those systemic problems.
Rather than addressing the root causes, i.e., overcrowding, poor hygiene, and inadequate animal welfare, the FDA’s approach allows routine antibiotic use to continue under the guise of “prevention.”
Effective antibiotics are a cornerstone of modern medicine. Once resistance spreads, we cannot simply create replacements overnight. Preserving these lifesaving drugs requires strong, enforceable public-health protections, not voluntary proposals shaped by industry.
What We’re Asking FDA to Do
To truly protect people and animals from antibiotic-resistant superbugs, the FDA must:
Reinstate clear public-health guardrails, consistent with GFI #152, by limiting antibiotic durations to no more than 21 days unless strong evidence shows a longer duration does not increase resistance risk.
Prohibit preventive use of antibiotics in animals that are not sick or injured, in line with World Health Organization recommendations.
Address the root causes of overuse by encouraging improved hygiene, reduced crowding, and better animal welfare practices.
Public health must come first. The FDA has both the authority and the responsibility to ensure that medically important antibiotics are preserved for when they are truly needed.